Table 1 Demographic and clinical characteristics of Cohort 1, 2 and 3.

From: Kynurenine pathway metabolomics predicts and provides mechanistic insight into multiple sclerosis progression

 

RRMS

SPMS

PPMS

HC

Cohort 1, n

50

20

17

49

 Female sex, n(%)

30 (60.0)

15 (75.0)

13 (76.5)

35 (71.4)

 Age in years, mean (+SD)A*

43.4 (9.4)

53.45 (9.7)

52.24 (8.8)

45.29 (11.7)

 Disease duration in year, mean (+SD)B*

6.92 (5.9)

16.5 (4.4)

16.18 (5.4)

N/A

 Severity, EDSS, median (quartiles)B*

2.0 (1.5, 3.4)

6.0 (3.4, 6.5)

5.5 (2.5, 6.0)

N/A

Cohort 2, n

44

15

  

 Female sex, n(%)

32 (72.7)

7 (46.7)

  

 Age in years, mean (+SD)A* Baseline 2 years follow-up

47.8 (10.1) 49.4 (10.2)

59.4 (10.7) 61.5 (10.7)

  

 Disease duration in year, mean (+SD)B* Baseline Follow-up

8.73 (8.4) 10.3 (8.4)

18.2 (9.7) 20.3 (9.9)

  

 Severity, EDSS, mean (+SD)B* Baseline Follow-up

3.7 (1.9) 3.8 (2.0)

6.8 (1.5) 6.9 (1.5)

  

Cohort 3, n

9

20

 

6

 Female sex, n(%)

6 (66.7)

14 (70.0)

 

4 (66.7)

 Age in years, mean (+SD)

49.2 (16.0)

49.7 (9.0)

 

43.67 (11.8)

  1. Abbreviations: RRMS = Relapsing-remitting multiple sclerosis; SPMS = secondary progressive multiple sclerosis; PPMS = primary progressive multiple sclerosis; HC = healthy controls; EDSS = Expanded Disability Status Scale; N/A = not applicable. SD = Standard deviation. AANOVA, Tukey HSD, BKruskal Wallis non-parametric test, *p < 0.001, indicating significant difference between RRMS and SPMS groups. Adjustment had been made accordingly in subsequent analysis.
Back to article page